Enantioselective determination of ondansetron and 8-hydroxyondansetron in human plasma from recovered surgery patients by liquid chromatography-tandem mass spectrometry

Journal of Analytical Toxicology

Volumn 34, Issue 9, 2010, Pages 581-586

  Musshoff, F ^a   Madea, B ^a   Stuber F ^a,b   Stamer, U M ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYONDANSETRON; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; ONDANSETRON; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; ENANTIOMER; ENANTIOSELECTIVITY; GENOTYPE; HUMAN; HUMAN CELL; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; SURGICAL PATIENT; TANDEM MASS SPECTROMETRY;

EID: 79954573818     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/34.9.581     Document Type: Article

References (31)

1. J.H. Ye, R. Ponnudurai, and R. Schaefer. Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev. 7: 199-213 (2001).
2. K.Y. Ho and T.J. Gan. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr.Opin. Anaesthesiol. 19: 606-611 (2006).
3. M. Aapro. 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology 69: 97-109 (2005).
4. T.J. Gan. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs 19: 225-238 (2005).
5. GlaxoSmithKline, Zofran (ondansetron hydrochloride) injection (prescribing information), 2006
6. K.H. Simpson and F.M. Hicks. Clinical pharmacokinetics of ondansetron. A review. J. Pharm. Pharmacol. 48: 774-781 (1996).
7. D.A. Saynor and C.M. Dixon. The metabolism of ondansetron. Eur. J. Cancer Clin. Oncol. 25(Suppl. 1): S75-S77 (1989).
8. V. Fischer, A.E. Vickers, F. Heitz, S. Mahadevan, J.P. Baldeck, P. Minery, and R. Tynes. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab. Dispos. 22: 269-274 (1994).
9. P. Sanwald, M. David, and J. Dow. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab. Dispos. 24: 602-609 (1996).
10. C.M. Dixon, P.V. Colthup, C.J. Serabjit-Singh, B.M. Kerr, C.C. Boehlert, G.R. Park, and M.H. Tarbit. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab. Dispos. 23: 1225-1230 (1995).
11. A. Butler, J.M. Hill, S.J. Ireland, C.C. Jordan, and M.B. Tyers. Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br. J. Pharmacol. 94: 397-412 (1988).
12. W.J. James. U.S. patent 5470868. Methods for treating emesis and nausea using optically pure R(+)ondansetron, 1993.
13. P.V. Colthupa and J.L. Palmer. The determination in plasma and pharmacokinetics of ondansetron. Eur. J. Cancer Clin. Oncol. 25(Suppl. 1): S71-S74 (1989).
14. M. Depot, S. Leroux, and G. Caille. High-resolution liquid chromatographic method using ultraviolet detection for determination of ondansetron in human plasma. J. Chromatogr. B Biomed. Sci. Appl. 693: 399-406 (1997).
15. X. Xu, M.G. Bartlett, and J.T. Stewart. Determination of ondansetron and its hydroxy metabolites in human serum using solid-phase extraction and liquid chromatography/positive ion electrospray tandem mass spectrometry. J. Mass Spectrom. 35: 1329-1334 (2000).
16. S. Bauer, E. Stormer, R. Kaiser, P.B. Tremblay, J. Brockmöller, and I. Roots. Simultaneous determination of ondansetron and tropisetron in human plasma using HPLC with UV detection. Biomed. Chromatogr. 16: 187-190 (2002).
17. D. Chandrasekar, S. Ramakrishna, and P.V. Diwan. A rapid, sensitive and validated method for the determination of ondansetron in human plasma by reversed-phase high-pressure liquid chromatography. Arzneimittelforschung 54: 655-659 (2004).
18. M. Siluveru and J.T. Stewart. Enantioselective determination of S-(+)- and R-(-)-ondansetron in human serum using derivatized cyclodextrin-modified capillary electrophoresis and solid-phase extraction. J. Chromatogr. B Biomed. Sci.Appl. 691: 217-222 (1997).
19. J.W. Kelly, L. He, and J.T. Stewart. High-performance liquid chromatographic separation of ondansetron enantiomers in serum using a cellulose-derivatized stationary phase and solid-phase extraction. J. Chromatogr. 622: 291-295 (1993).
20. J. Liu and J.T. Stewart. High-performance liquid chromatographic analysis of ondansetron enantiomers in human serum using a reversed-phase cellulose-based chiral stationary phase and solidphase extraction. J. Chromatogr. B Biomed. Sci. Appl. 694: 179-184 (1997).
21. K. Liu, X. Dai, D. Zhong, and X. Chen. Quantitative determination of ondansetron in human plasma by enantioselective liquid chromatography- tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 864: 129-136 (2008).
22. W.D. Figg, G.E. Dukes, J.F. Pritchard, D.J. Hermann, H.R. Lesesne, S.W. Carson, S.S. Songer, J.R. Powell, and L.J. Hak. Pharmacokinetics of ondansetron in patients with hepatic insufficiency. J. Clin. Pharmacol. 36: 206-215 (1996).
23. E.I. Ashforth, J.L. Palmer, A. Bye, and A. Bedding. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. Br. J. Clin. Pharmacol. 37: 389-391 (1994).
24. R. Kaiser, O. Sezer, A. Papies, S. Bauer, C. Schelenz, P.B. Tremblay, K. Possinger, I. Roots, and J. Brockmoller. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J. Clin. Oncol. 20: 2805-2811 (2002).
25. K.A. Candiotti, D.J. Birnbach, D.A. Lubarsky, F. Nhuch, A. Kamat, W.H. Koch, M. Nikoloff, L. Wu, and D. Andrews. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology 102: 543-549 (2005).
26. J. Sistonen, S. Fuselli, J.U. Palo, N. Chauhan, H. Padh, and A. Sajantila. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet. Genomics 19: 170-179 (2009).
27. 450P Drug Interaction Table: http://medicine.iupui.edu/clinpharm/ ddis/table.asp.
28. U.M. Stamer and F. Stüber. The pharmacogenetics of analgesia. Expert Opin. Pharmacother. 8: 2235-2245 (2007).
29. M. Ingelman-Sundberg, S.C. Sim, A. Gomez, and C. Rodriguez-Antona. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116: 496-526 (2007).
30. M. Eichelbaum, M. Ingelman-Sundberg, and W.E. Evans. Pharmacogenomics and individualized drug therapy. Annu. Rev.Med. 57: 119-137 (2006).
31. S. Zhong and M. Romkes. Pharmacogenomics. Methods Mol. Biol. 520: 231-245 (2009).